Chandler Robinson Monopar Therapeutics (MNPR) insider trading activity

Chandler Robinson is Chief Executive Officer of Monopar Therapeutics. Currently has a direct ownership of 73,472 shares of MNPR, which is worth approximately $5.89 Million. The most recent transaction as insider was on Mar 31, 2023, when has been sold 4,286 shares (Common Stock) at a price of $1.39 per share, resulting in proceeds of $5,957. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 73.5K

0% 3M change

30.82% 12M change

Total Value Held $5.89 Million

Chandler Robinson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 31 2023	SELL Payment of exercise price or tax liability	$5,957 $1.39 p/Share	4,286 Reduced 4.73%	86,354 Common Stock
Mar 31 2023	BUY Exercise of conversion of derivative security	-	13,911 Added 13.31%	90,640 Common Stock
Jan 01 2023	SELL Payment of exercise price or tax liability	$5,514 $2.37 p/Share	2,327 Reduced 2.94%	76,729 Common Stock
Jan 01 2023	BUY Exercise of conversion of derivative security	-	6,723 Added 7.84%	79,056 Common Stock
Dec 31 2022	SELL Payment of exercise price or tax liability	$11,409 $2.37 p/Share	4,814 Reduced 6.24%	72,333 Common Stock
Dec 31 2022	BUY Exercise of conversion of derivative security	-	13,912 Added 15.28%	77,147 Common Stock
Sep 30 2022	SELL Payment of exercise price or tax liability	$6,197 $1.52 p/Share	4,077 Reduced 6.06%	63,235 Common Stock
Sep 30 2022	BUY Exercise of conversion of derivative security	-	13,911 Added 17.13%	67,312 Common Stock
Jun 30 2022	SELL Payment of exercise price or tax liability	$16,098 $2.3 p/Share	6,999 Reduced 11.59%	53,401 Common Stock
Jun 30 2022	BUY Exercise of conversion of derivative security	-	23,882 Added 28.34%	60,400 Common Stock
Mar 31 2022	SELL Payment of exercise price or tax liability	$2,945 $2.55 p/Share	1,155 Reduced 3.07%	36,518 Common Stock
Mar 31 2022	BUY Exercise of conversion of derivative security	-	3,941 Added 9.47%	37,673 Common Stock
Jan 01 2022	SELL Payment of exercise price or tax liability	$7,470 $3.21 p/Share	2,327 Reduced 6.45%	33,732 Common Stock
Jan 01 2022	BUY Exercise of conversion of derivative security	-	6,724 Added 15.72%	36,059 Common Stock
Dec 31 2021	SELL Payment of exercise price or tax liability	$4,378 $3.21 p/Share	1,364 Reduced 4.44%	29,335 Common Stock
Dec 31 2021	BUY Exercise of conversion of derivative security	-	3,941 Added 11.38%	30,699 Common Stock
Sep 30 2021	SELL Payment of exercise price or tax liability	$5,625 $4.87 p/Share	1,155 Reduced 4.14%	26,758 Common Stock
Sep 30 2021	BUY Exercise of conversion of derivative security	-	3,941 Added 12.37%	27,913 Common Stock
Jun 30 2021	SELL Payment of exercise price or tax liability	$13,606 $5.89 p/Share	2,310 Reduced 8.79%	23,972 Common Stock
Jun 30 2021	BUY Exercise of conversion of derivative security	-	7,883 Added 23.07%	26,282 Common Stock
Jan 01 2021	SELL Payment of exercise price or tax liability	$14,241 $6.12 p/Share	2,327 Reduced 11.23%	18,399 Common Stock
Jan 01 2021	BUY Exercise of conversion of derivative security	-	6,724 Added 24.5%	20,726 Common Stock

Chandler Robinson

Chief Executive Officer

Wilmette, IL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MNPR shares.

Notify only if

Value

Insider Trading

Get notified when an Monopar Therapeutics insider buys or sells MNPR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Monopar Therapeutics

Track Activities on MNPR

Account